288 related articles for article (PubMed ID: 12404155)
1. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
[TBL] [Abstract][Full Text] [Related]
2. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
Kulkosky J; Pomerantz RJ
Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
[TBL] [Abstract][Full Text] [Related]
3. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
7. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.
Kwara A; Delong A; Rezk N; Hogan J; Burtwell H; Chapman S; Moreira CC; Kurpewski J; Ingersoll J; Caliendo AM; Kashuba A; Cu-Uvin S
Clin Infect Dis; 2008 Mar; 46(5):719-25. PubMed ID: 18220480
[TBL] [Abstract][Full Text] [Related]
9. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
10. Eliminating HIV-1 reservoirs.
Pomerantz RJ
Curr Opin Investig Drugs; 2002 Aug; 3(8):1133-7. PubMed ID: 12211403
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
12. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
13. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
14. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
17. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.
Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
Clin Infect Dis; 2002 Dec; 35(12):1541-8. PubMed ID: 12471575
[TBL] [Abstract][Full Text] [Related]
18. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S; Duval X; Joly V; Descamps D; Matheron S; Costagliola D;
Clin Infect Dis; 2003 Dec; 37(11):1517-26. PubMed ID: 14614675
[TBL] [Abstract][Full Text] [Related]
20. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
